Methylene Blue in the Treatment of Neuropsychiatric Disorders (2019)

Peer-Reviewed Study · Alda M · August 2019

Alda M, 2019-08: Narrative review of methylene blue in psychiatry describing antidepressant, anxiolytic and neuroprotective properties and calling the bipolar results particularly promising, while cautioning that methylene blue inhibits monoamine oxidase A.

Particularly promising results have been obtained in both short- and long-term treatment of bipolar disorder.

abstract

Alda M, 2019-08: Narrative review of methylene blue in psychiatry describing antidepressant, anxiolytic and neuroprotective properties and calling the bipolar results particularly promising, while cautioning that methylene blue inhibits monoamine oxidase A. Study type: narrative review (secondary source, not primary evidence). N/A. Country of authors not stated in abstract. No dose. Funders/conflicts: not stated in abstract – check the paper's disclosure section. Recorded because it is the review most often cited for the psychiatric uses; it does not add primary data. Also filed as MTC-076 (claims C11, C6). Study type: review.